Trastuzumab deruxtecan has also shown promise in previously treated ERBB2-low metastatic BC, as both the DESTINY-BREAST04 and DESTINY-BREAST06 phase 3 clinical trials demonstrated longer progression-free survival after treatment with trastuzumab deruxtecan vs the physician’s choice of chemotherapy.41,42. This evidence concerns the gene ERBB2 and breast cancer.